
Hormonal fluctuations affect not only women’s emotional experiences but also their cognitive abilities. Estrogen levels change substantially throughout a woman’s life, including during puberty, pregnancy, and menopause, as well as during the menstrual cycle. These fluctuations are associated with changes in brain structure, function, and neural networks.
Hormonal changes were long considered a confounding factor in neuroscience research, leading to the frequent exclusion of women from studies. However, “the menstrual cycle offers a fantastic opportunity to study neuroplasticity,” emphasized Julia Sacher, MD PhD, professor of cognitive neuroendocrinology at the Medical Faculty of Leipzig University Hospital and the Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany, during a plenary session at the 39th Congress of the European College of Neuropsychopharmacology (ECNP) in Munich, Germany.
Women’s health remains significantly underrepresented in neuroscience research, explained Sacher, who also heads the Leipzig Center for Women’s Health and Gender Medicine. Conditions such as postpartum depression (PPD) and premenstrual dysphoric disorder (PMDD) often go unrecognized. Of an estimated 2 million peer-reviewed neuroscience articles published over the past 25 years, fewer than 0.5% have addressed women’s health.
Modern imaging techniques, including PET scans, offer new ways to study hormone-dependent processes in the brain. PET can reveal changes in neuronal receptor activity and track hormone-related fluctuations in neurotransmitter systems, including serotonin and dopamine. The goal is to better understand the neurobiological mechanisms involved in psychiatric disorders and develop sex-specific treatment approaches.
Sacher and colleagues showed the close link between hormonal changes and neurotransmitter systems in neuroimaging studies of PPD. Up to 15% of women develop clinically significant PPD within 4 weeks of giving birth. The condition is often preceded by the so-called “postpartum blues,” characterized by crying without an apparent reason, irritability, anxiety, and insomnia. Postpartum blues are considered a risk factor for PPD.
The research focused on monoamine oxidase A (MAO-A), an enzyme that plays a key role in neurotransmitter breakdown. Researchers used radiolabeled tracers that bind to MAO-A and can be visualized with PET to measure the enzyme’s concentration in the brain after childbirth.
After childbirth, estrogen levels fall by a factor of 100-1000. At the same time, Sacher and her team observed an increase of more than 40% in MAO-A concentrations in several brain regions within the first 5 days after delivery.
Further research found increased MAO-A concentrations in the prefrontal and anterior cingulate cortices, particularly in women with PPD or individual symptoms within the PPD spectrum. The enzyme is found predominantly on the outer mitochondrial membrane of glial cells and noradrenaline-releasing neurons.
The regional increase in MAO-A concentrations could potentially serve as an early biomarker for PPD during the postpartum period. The findings also point to a neurobiological component of the disorder associated with the sharp decline in estrogen after childbirth. PPD therefore cannot be explained solely by psychosocial factors.
PMDD and Hormonal Sensitivity
According to the authors of the review article, fluctuations in estrogen and progesterone during the menstrual cycle also have substantial clinical implications. This is particularly evident in PMDD, which affects approximately 3%-8% of menstruating women. Neurobiological findings suggest that altered sensitivity of the central nervous system to hormonal fluctuations plays a key role.
PMDD is a hormone-dependent mood disorder in which symptoms occur during the second half of the menstrual cycle, known as the luteal phase, and subside with the onset of menstruation. Affected women may experience pronounced mood swings, irritability, anger, severe inner restlessness, and anxiety. Other symptoms include sleep disturbances, difficulty concentrating, food cravings, and painful breast tenderness. These symptoms can substantially impair daily functioning and quality of life.
One proposed mechanism is excessive neuronal sensitivity to normal cyclical changes in estrogen and progesterone levels. The hormonal fluctuations themselves are not abnormal; instead, the brain’s response to them is altered.
During the luteal phase, MAO-A activity and the availability of the serotonin transporter in the brain increase, attenuating serotonergic signaling. PET studies showed significantly increased serotonin transporter binding in women with PMDD during the premenstrual phase compared with the first half of the menstrual cycle. This finding is consistent with increased serotonin reuptake from the synaptic cleft. The same effect was not observed in healthy participants.
Attention-Deficit/Hyperactivity Disorder (ADHD): Why Symptoms May Worsen Before Menstruation
Hormonal fluctuations can affect not only cycle-related conditions such as PMDD but also existing psychiatric disorders, including ADHD. Many women with ADHD report increased inattention and impulsivity during the premenstrual phase.
PET studies have linked these changes to the dopaminergic and noradrenergic systems. When estrogen levels fall during the late luteal phase, dopaminergic activity in the prefrontal cortex also decreases. This may exacerbate ADHD symptoms and reduce the response to stimulant medications.
Initial case reports and clinical observations suggest that adjusting stimulant treatment or dosage during the late luteal phase may help alleviate premenstrual worsening of symptoms. However, evidence for cycle-based adjustments to ADHD medication remains limited, and this approach requires further study.
The menstrual cycle provides a biological opportunity to better understand psychiatric disorders and tailor treatment to hormonal changes. Accounting for cycle-dependent neurobiological processes could contribute to more individualized treatment approaches.
“When women’s brain health improves, the brain health of everyone improves,” Sacher concluded.
This story was translated from Medscape’s German edition.
